<DOC>
	<DOCNO>NCT01432249</DOCNO>
	<brief_summary>Enbrel first approve new medicine 06 Oct 2003 Korea indication Pediatric Psoriasis approve 23 Sep 2009 . However , require new indication approve Korea Food Drug Administration ( KFDA ) , safety efficacy information new indication provide minimum 600 subject administer set routine practice initial 4 year new indication approve .</brief_summary>
	<brief_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis</brief_title>
	<detailed_description>All patient enrol meet usual prescribe criterion Enbrel psoriasis per local product information usage .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Children adolescent age 8 year 17 year time consent 2 . Chronic severe psoriasis patient inadequately control , intolerant , systemic therapy phototherapies 1 . Patients know hypersensitivity Enbrel component product 2 . Patients active infection include chronic localized infection tuberculosis ( Treatment Enbrel initiate )</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>pediatric psoriasis</keyword>
	<keyword>enbrel</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>